This proposal brings together three experienced groups proposing an integrated series of experiments using adeno-associated virus (Gainesville) in rodent (Lund) and nonhuman primate (Rush) models of Parkinson's disease (PD). A concensus is emerging that site-specific rAAV-mediated striatal L-dopa delivery might be a useful strategy for treating PD. However, clinical trials using this approach cannot even begin to be considered before critical efficacy and safety studies need to be performed. Towards this end, three research themes will be explored in this application. First we will perform studies in monkeys designed at vector optimization. We will determine the optimal AAV serotype in nonhuman primates and establish the optimal ratio of TH to GTPCH1.Currently, a 1:1 ratio is utilized. However, we believe that a higher ratio will be more effective due to the kinestics of GTPCH1 and thus we will be able to deliver more TH, and ultimately more LDOPA. These studies will also provide critical """"""""scaling-up"""""""" data in primates that will be relevant for futures clinical trials. The second research theme is efficacy. The TH/GTPCH1 gene delivery approach has already been shown to be effective in reversing drug-induced and spontaneous motor deficits in rodent models of PD. The present proposal will establish efficacy in MPTP treated monkeys, the best animal model available for PD.
The third aim i s safety. With regards to functional safety, our main concern is dyskinesias. We have already demonstrated that rAAV-Ldopa reverses already manifest dyskinesias in 6-OHDA lesioned rats and have new data demonstrating that rAAV-LDOPA prevents the emergence of dyskinesias. IN this new application, we will evaluate the role of serotonin in the expression of dyskinesias in rats. Further, the effect of """"""""hot spot"""""""" versus """"""""widespread"""""""" delivery of TH/GTPCH1 upon efficacy and dyskinesias will be evaluated. The monkey model of dyskinesias is recognized as the best available for the study of dyskinesias. In the present study we will test the hypothesis that gene delivered levodopa can both reverse already manifest Idopa dyskinesias and delay the emergence of new dyskinesias. These studies will determine the safety and efficacy of gene delivery of LDOPA and determine whether this approach is appropriate for clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS055143-04
Application #
7743381
Study Section
Clinical Neuroplasticity and Neurotransmitters Study Section (CNNT)
Program Officer
Sieber, Beth-Anne
Project Start
2007-04-10
Project End
2011-11-30
Budget Start
2009-12-01
Budget End
2011-11-30
Support Year
4
Fiscal Year
2010
Total Cost
$513,992
Indirect Cost
Name
Rush University Medical Center
Department
Type
DUNS #
068610245
City
Chicago
State
IL
Country
United States
Zip Code
60612
Kelly, Leo P; Carvey, Paul M; Keshavarzian, Ali et al. (2014) Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 29:999-1009
Cederfjäll, Erik; Nilsson, Nathalie; Sahin, Gurdal et al. (2013) Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Sci Rep 3:2157
Janic, Branislava; Jafari-Khouzani, Kourosh; Babajani-Feremi, Abbas et al. (2012) MRI tracking of FePro labeled fresh and cryopreserved long term in vitro expanded human cord blood AC133+ endothelial progenitor cells in rat glioma. PLoS One 7:e37577
Cederfjäll, Erik; Sahin, Gurdal; Kirik, Deniz et al. (2012) Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Mol Ther 20:1315-26
Kordower, Jeffrey H; Dodiya, Hemraj B; Kordower, Adam M et al. (2011) Transfer of host-derived ? synuclein to grafted dopaminergic neurons in rat. Neurobiol Dis 43:552-7
Bjorklund, Tomas; Carlsson, Thomas; Cederfjall, Erik Ahlm et al. (2010) Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 133:496-511
Dodiya, Hemraj B; Bjorklund, Tomas; Stansell 3rd, James et al. (2010) Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18:579-87
Bjorklund, Tomas; Hall, Helene; Breysse, Nathalie et al. (2009) Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. J Neurochem 111:355-67
Ramaswamy, Shilpa; Soderstrom, Katherine E; Kordower, Jeffrey H (2009) Trophic factors therapy in Parkinson's disease. Prog Brain Res 175:201-16
Isacson, Ole; Kordower, Jeffrey H (2008) Future of cell and gene therapies for Parkinson's disease. Ann Neurol 64 Suppl 2:S122-38